Floatz logo

Tocilizumab

Brain Diseases

Zhujiang Hospitalmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Brain Diseases cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Donanemab
Eli Lilly and Company
Phase 3B

View all 43 →

Same molecule, other indications

Tocilizumab is also rated in:

rheumatoid arthritisDormant
BB
Indicative ·
66 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
65 / 100
View asset →
acute chest syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →